About Nativis
Nativis is a company based in Seattle (United States) founded in 2002.. Nativis has raised $28.43 million across 9 funding rounds. The company has 13 employees as of December 31, 2010. Nativis operates in a competitive market with competitors including ChemoTech, IGEA, RanD and Papyrus Therapeutics, among others.
- Headquarter Seattle, United States
- Employees 13 as on 31 Dec, 2010
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$28.43 M (USD)
in 9 rounds
-
Latest Funding Round
$4.12 M (USD), Series B
Nov 14, 2018
-
Investors
-
Employee Count
13
as on Dec 31, 2010
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Nativis
Nativis has successfully raised a total of $28.43M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $4.12 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series B — $4.1M
-
First Round
First Round
(01 Jul 2003)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2018 | Amount | Series B - Nativis | Valuation |
investors |
|
| May, 2017 | Amount | Series B - Nativis | Valuation |
investors |
|
| Feb, 2017 | Amount | Series B - Nativis | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Nativis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Nativis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nativis Comparisons
Competitors of Nativis
Nativis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ChemoTech, IGEA, RanD and Papyrus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of electroporation devices for the treatment of cancer
|
|
| domain | founded_year | HQ Location |
Orthopedic medical devices to promote reparative osteogenesis and joint protection
|
|
| domain | founded_year | HQ Location |
Medical devices for surgical oncology are developed using extracorporeal technologies.
|
|
| domain | founded_year | HQ Location |
Develops therapies for tumor suppression in various cancers through scientific research.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nativis
Frequently Asked Questions about Nativis
When was Nativis founded?
Nativis was founded in 2002 and raised its 1st funding round 1 year after it was founded.
Where is Nativis located?
Nativis is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is Nativis a funded company?
Nativis is a funded company, having raised a total of $28.43M across 9 funding rounds to date. The company's 1st funding round was a Series B of $10M, raised on Jul 01, 2003.
How many employees does Nativis have?
As of Dec 31, 2010, the latest employee count at Nativis is 13.
What does Nativis do?
Nativis was founded in 2002 in Seattle, United States, and operates in the medical device sector focused on oncology and related conditions. A therapeutic device is developed that employs ultra-low radio frequency energy to target metabolic pathways at molecular and genetic levels. Treatments are provided for brain cancer, lung cancer, other cancers, inflammatory diseases, and chronic pain, with operations centered in the United States.